Drug Trial Radar · NCT03499873
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
448
Actual
Start
Mar 28, 2018
Primary completion
Oct 31, 2018
Study completion Dec 18, 2018
Sponsor
- Lead sponsor
- Actavis Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic suspension), 0.3% of Alcon Laboratories, Inc. for the treatment of pain and inflammation associated with cataract surgery.
Conditions
- Cataract
Interventions
Nepafenac 0.3% Oph SuspDrug
Nepafenac 0.3% Ophthalmic suspension (experimental product)
PlacebosDrug
Placebo
Nepafenac 0.3% Oph Susp (reference)Drug
Nepafenac 0.3% Ophthalmic suspension (Innovator)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cure at Day 14Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Key-Whitman Eye Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.